RGBP.P Stock Overview
Focuses on the development of regenerative medical applications in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Regen BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.063 |
| 52 Week High | US$1.17 |
| 52 Week Low | US$0.03 |
| Beta | 2.72 |
| 1 Month Change | -22.01% |
| 3 Month Change | -60.19% |
| 1 Year Change | -91.05% |
| 3 Year Change | -99.68% |
| 5 Year Change | -96.42% |
| Change since IPO | -99.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| RGBP.P | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.0% | -3.8% | -2.7% |
| 1Y | -91.1% | -2.6% | 23.4% |
Return vs Industry: RGBP.P underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: RGBP.P underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| RGBP.P volatility | |
|---|---|
| RGBP.P Average Weekly Movement | 113.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RGBP.P's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RGBP.P's weekly volatility has increased from 89% to 114% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1 | David Koos | regenbiopharmainc.com |
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is involved in the development of its products, and therapies, including HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6.
Regen BioPharma, Inc. Fundamentals Summary
| RGBP.P fundamental statistics | |
|---|---|
| Market cap | US$788.74k |
| Earnings (TTM) | -US$867.25k |
| Revenue (TTM) | US$236.56k |
3.3x
P/S Ratio-0.9x
P/E RatioIs RGBP.P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGBP.P income statement (TTM) | |
|---|---|
| Revenue | US$236.56k |
| Cost of Revenue | US$0 |
| Gross Profit | US$236.56k |
| Other Expenses | US$1.10m |
| Earnings | -US$867.25k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.082 |
| Gross Margin | 100.00% |
| Net Profit Margin | -366.61% |
| Debt/Equity Ratio | -15.3% |
How did RGBP.P perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:56 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Regen BioPharma, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|